Statements (106)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
acquired by a larger pharmaceutical company in 2021
|
| gptkbp:advocates_for |
supports patient advocacy initiatives
|
| gptkbp:awards |
received various industry awards
received industry awards for innovation |
| gptkbp:ceo |
Gal Cohen
|
| gptkbp:clinical_trial |
publishes results of clinical trials
conducts clinical research studies conducts trials in multiple phases Phase 3 trials for Nexo Brid collects clinical data for product validation ongoing clinical development programs strong clinical evidence supporting product efficacy analyzes clinical data for product efficacy conducted for Nexo Brid supports its products with clinical evidence |
| gptkbp:collaborations |
collaborates with various research institutions
with various academic institutions |
| gptkbp:committee |
has an advisory board of experts
|
| gptkbp:community_engagement |
engages in community health initiatives
engages with the medical community |
| gptkbp:community_involvement |
engages in community outreach programs
|
| gptkbp:community_support |
supports community health initiatives.
|
| gptkbp:conflict |
addresses market challenges in wound care
|
| gptkbp:develops |
gptkb:Nexo_Brid
Eschar Ex |
| gptkbp:economic_impact |
pursues market expansion opportunities
|
| gptkbp:education |
provides patient education resources
|
| gptkbp:employees |
growing workforce
growing employee count |
| gptkbp:feedback |
collects patient feedback for product improvement
|
| gptkbp:financial_performance |
publishes quarterly financial reports
reported revenue growth in 2021 |
| gptkbp:focus |
developing and commercializing innovative therapies for wound care
|
| gptkbp:focuses_on |
wound care
|
| gptkbp:founded |
gptkb:2001
|
| gptkbp:future_plans |
has future plans for product expansion
|
| gptkbp:global_presence |
has an international presence
expanding international presence |
| gptkbp:governed_by |
engages in business development activities
|
| gptkbp:grants |
receives research grants
|
| gptkbp:headquarters |
gptkb:Yavne,_Israel
|
| gptkbp:healthcare |
provides healthcare education resources
promotes healthcare innovation contributes to global health initiatives focuses on therapeutic innovation |
| https://www.w3.org/2000/01/rdf-schema#label |
Medi Wound
|
| gptkbp:innovation |
drives innovation in wound care solutions
drives innovation in wound care |
| gptkbp:invention |
holds multiple patents for its products
|
| gptkbp:investment |
attracts institutional investors
public and private investors attracted significant investments for R& D attracts investments for R& D |
| gptkbp:language_of_instruction |
has a robust product pipeline
diverse pipeline of wound care products |
| gptkbp:market |
conducts market research for product development
global market for wound care launched new products in 2021 launched Nexo Brid in various markets |
| gptkbp:marketing_strategy |
focused on expanding market presence
develops targeted market strategies |
| gptkbp:mission |
improve patient outcomes in wound healing
to improve patient outcomes in wound care |
| gptkbp:partnership |
gptkb:military_unit
Medi Wound and the U. S. Army |
| gptkbp:partnerships |
forms partnerships with healthcare organizations
strategic partnerships with healthcare providers establishes clinical partnerships for trials |
| gptkbp:platform |
develops enzymatic debridement products
|
| gptkbp:products |
gptkb:Nexo_Brid
invests in product development Eschar Ex |
| gptkbp:provides_information_on |
contributes to clinical guidelines for wound care
|
| gptkbp:publishes |
publishes research in scientific journals
publishes scientific research |
| gptkbp:reach |
has a global reach in distribution
|
| gptkbp:receives_funding_from |
secured research funding from government grants
|
| gptkbp:regulatory_compliance |
ensures compliance with regulations
ensures regulatory compliance in all markets received FDA approval for Nexo Brid manages regulatory affairs effectively |
| gptkbp:research_areas |
gptkb:Fire_Department
|
| gptkbp:research_focus |
biologics for wound healing
biologics and advanced wound care |
| gptkbp:safety_features |
prioritizes patient safety in product development
|
| gptkbp:scholarships |
offers patient support programs
|
| gptkbp:side_effect |
aims to have a positive impact on healthcare
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:supply_chain |
has a global supply chain
develops a robust supply chain for products optimizes supply chain management |
| gptkbp:sustainability |
committed to sustainable practices
committed to sustainable practices in operations |
| gptkbp:symbol |
MDWD
|
| gptkbp:technology |
engages in technology transfer initiatives
engages in technology transfer agreements proprietary technology for wound care |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
focuses on improving clinical outcomes
focuses on improving patient outcomes |
| gptkbp:type_of_care |
enhances patient care through its products
|
| gptkbp:vision |
to be a leader in advanced wound care solutions
|
| gptkbp:website |
www.mediwound.com
|
| gptkbp:bfsParent |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:bfsLayer |
4
|